Sulfamethoxazole trimethoprim, often dispensed under combination antibiotic labels, is one of the most commonly prescribed antibiotics for urinary tract infections, respiratory infections, and certain skin infections. Employees who take it sometimes ask whether it can trigger a false positive on a workplace urine drug screen. The short answer, based on the published record, is that there is no well documented cross reactivity between sulfamethoxazole trimethoprim and the immunoassay classes used on standard 5, 10, or 12 panel workplace drug tests. This article explains what the drug is, how screening and confirmation actually work, and what an employer or employee should do if a result is ever disputed.
What sulfamethoxazole trimethoprim is and its drug class
Sulfamethoxazole trimethoprim combines a sulfonamide antibiotic (sulfamethoxazole) with a folate pathway inhibitor (trimethoprim). The combination is sold under several brand and generic labels and is used to treat bacterial infections, not viral or fungal ones. The current current prescribing information is maintained on DailyMed, the National Library of Medicine's repository of drug labeling, and can be reviewed directly on the sulfamethoxazole and trimethoprim label on DailyMed. The label describes dosing, warnings, and adverse reactions, but it does not list workplace urine drug screening interference as a known effect.
Is sulfamethoxazole trimethoprim a controlled substance
No. Sulfamethoxazole trimethoprim is not a controlled substance under federal law. The Drug Enforcement Administration maintains the federal schedules of controlled substances, which can be reviewed at the DEA Office of Diversion Control schedules page, and the current regulatory text for those schedules is published in the Code of Federal Regulations and kept current at eCFR Title 21 Part 1308, Schedules of Controlled Substances. Sulfonamide antibiotics and folate inhibitors like trimethoprim do not appear on any of the five federal schedules. That status alone does not rule out a laboratory cross reactivity question, which is a separate, chemistry based issue from legal scheduling.
What standard immunoassay panels actually screen for
Workplace urine cups and dip cards use immunoassay screening, a chemistry method built to flag specific drug classes by targeting antibody binding to a parent drug or its metabolites. A standard 5, 10, or 12 panel test is built around classes such as amphetamines, opiates, cocaine metabolite, THC metabolite, PCP, barbiturates, benzodiazepines, methadone, and a few expanded classes depending on the panel. Sulfamethoxazole and trimethoprim are structurally unrelated to every one of those target classes. They are not amphetamines, not opiates, not benzodiazepines, and not any of the other drug families immunoassay antibodies are designed to bind. That structural distance is the main reason there is no established interference pathway published for this antibiotic on standard screens.
What the published record says about cross reactivity
This is the key point for anyone searching this question: no published cross reactivity between sulfamethoxazole trimethoprim and the standard immunoassay drug classes has been established in the literature that American Screening Corporation could verify through government sources. That is different from saying the combination is impossible to ever show an unusual result. It means the specific, well characterized cross reactivity findings that exist for some other antibiotics have not been documented for this one. Employers and employees should treat any claim that this antibiotic "will" or "will not" cause a false positive with caution, and should not rely on anecdotal reports over laboratory confirmation.
This stands in sharp contrast to two antibiotic classes that do have documented interference patterns on certain immunoassays. Rifampin, used for tuberculosis and some other infections, has a well known history of producing a false positive opiate screen result along with an orange discoloration of urine, which American Screening covers in detail in its article on whether rifampin causes a false positive drug test. Fluoroquinolone antibiotics such as ofloxacin and levofloxacin have also been associated with opiate immunoassay cross reactivity in some screening platforms. Sulfamethoxazole trimethoprim is chemically distinct from both rifampin and the fluoroquinolone class, which is part of why it does not share their documented interference profile.
Antibiotics and immunoassay interference, side by side
| Antibiotic | Drug class | Published cross reactivity concern |
|---|---|---|
| Sulfamethoxazole trimethoprim | Sulfonamide plus folate inhibitor | No well documented cross reactivity on standard panels |
| Rifampin | Rifamycin | Documented association with false positive opiate screens and orange urine |
| Ofloxacin and levofloxacin | Fluoroquinolone | Reported opiate immunoassay cross reactivity on some platforms |
| Amoxicillin | Penicillin | No well documented cross reactivity on standard panels |
Why a presumptive screen is never the final word
Immunoassay screening is designed to be sensitive, which means it is built to flag anything close to a target compound rather than risk missing a true positive. That tradeoff is exactly why a non negative immunoassay result is called presumptive, not final. Any non negative screen on a laboratory based program should be sent for confirmation using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS), methods that identify the exact molecule present rather than a general chemical family. Confirmation testing is the step that distinguishes a true amphetamine or opiate positive from a screen that reacted to an unrelated compound. If sulfamethoxazole trimethoprim were ever the cause of an unusual screen reading, GC/MS or LC/MS confirmation would not report it as the target drug, because the two molecules are not the same and the confirmation method does not mistake one for the other.
The MRO review and prescription documentation
Federally regulated testing programs, including those covering DOT safety sensitive positions, require that any confirmed non negative result go through review by a Medical Review Officer (MRO) before it is reported to the employer. The MRO's role, procedures, and the specific duty to consider legitimate medical explanations, including current prescriptions, are set out in 49 CFR Part 40 on the eCFR. An employee who is taking a prescribed antibiotic, or any other medication, should be prepared to provide the prescription information, the prescriber's contact information, and the pharmacy label if the MRO requests it. This is a documentation step, not a medical determination made by the employer, and it is the correct channel for resolving a disputed result rather than guessing about a specific drug's effects. For a deeper look at how that review works end to end, see the American Screening article on the Medical Review Officer process.
What employers should do with a disputed result
Employers should never diagnose, speculate about dosing, or tell an employee what a medication does or does not do chemically. The correct steps are procedural: confirm any non negative screen with GC/MS or LC/MS before taking action, route confirmed results through the MRO or an equivalent qualified reviewer for non DOT programs, and let the employee submit prescription documentation through that review rather than directly to a supervisor. Written policies should spell out this sequence in advance so that both the employer and the employee know what happens if a presumptive result needs a second look. General guidance on substance use program design and statutory authority is maintained by the Substance Abuse and Mental Health Services Administration at its statutes, regulations, and guidelines page.
Panel and cup selection for employers running antibiotic heavy workforces
Workplaces with higher rates of short term antibiotic use, such as healthcare, food service, or outdoor labor environments, do not need a different panel because of antibiotics specifically. The standard immunoassay classes on a 5, 10, or 12 panel cup are not built to target antibiotics, so no special accommodation is required there. What does matter is picking a reliable screening device and following it with a legitimate laboratory confirmation pathway, since confirmation, not panel choice, is what resolves questions like this one. American Screening Corporation's drug test cup collection includes multi panel configurations suited to a range of program designs, and businesses building or restocking a wholesale testing program can review account options through the wholesale portal.
Frequently asked questions
Does sulfamethoxazole trimethoprim show up as a specific drug on a drug test?
No. Standard workplace immunoassay panels are not built to detect sulfonamide antibiotics or trimethoprim, and there is no dedicated strip or cup target for this medication.
Can sulfamethoxazole trimethoprim cause a false positive on a standard panel?
There is no well documented cross reactivity between this antibiotic and the standard 5, 10, or 12 panel immunoassay classes based on the sources American Screening could verify. Any non negative result should still go through confirmation testing rather than being attributed to the antibiotic without evidence.
Is sulfamethoxazole trimethoprim a controlled substance?
No. It does not appear on any federal controlled substance schedule maintained under eCFR Title 21 Part 1308.
How is a false positive ruled out if an employee is taking this antibiotic?
Through laboratory confirmation using GC/MS or LC/MS, followed by Medical Review Officer review of prescription documentation under 49 CFR Part 40 for federally regulated programs.
Which antibiotics actually have documented cross reactivity concerns?
Rifampin has a documented association with false positive opiate screens, and fluoroquinolones such as ofloxacin and levofloxacin have reported opiate immunoassay cross reactivity on some platforms. Sulfamethoxazole trimethoprim does not share this documented profile.
Should an employer ask what medication caused a non negative result?
Employers should not try to determine this themselves. Prescription documentation is reviewed by the Medical Review Officer or an equivalent qualified reviewer, not by supervisors or HR staff making a medical judgment.
This article is general information for employers and employees, not legal or medical advice. Testing programs should consult qualified legal counsel and a Medical Review Officer for decisions about specific results or policies.